Clinical Trial Update: HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial update for HuMax-CD4 in T cell lymphoma has completed recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Lymphoma

Drugs mentioned

• HuMax-CD4

Snippet

Sponsor: Emergent BioSolutions | Conditions: T Cell Lymphoma | Phase 2, Phase 3 | Status: COMPLETED